Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 15/20 | 0.70 |
| ▸ | MAOA | P21397 | 12/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21602513 | 0.88 | RXFP1 (1.00) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25522687 | 0.85 | RXFP1 (0.78) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL21602500 | 0.83 | RXFP1 (0.79) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25522699 | 0.82 | RXFP1 (0.74) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL3098630 | 0.82 | RXFP1 (0.78) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25522708 | 0.82 | RXFP1 (0.74) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25241641 | 0.81 | RXFP1 (0.72) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25204131 | 0.79 | MAOB (1.00) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25209652 | 0.78 | RXFP1 (0.67) | RXFP1MEN1KMT2AMAOBMAOA | |
| SCHEMBL25236490 | 0.77 | RXFP1 (0.65) | RXFP1MEN1KMT2AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236810-B2 | Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-7838528-B2 | Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070265284-A1 | SUBSTITUTED 8-AMINOALKYLTHIOXANTHINES, AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1778689-A1 | SUBSTITUTED 8-AMINOALKYLTHIO-XANTHINES, AND THE USE THEREOF AS INHIBITORS OF THE DIPEPTIDYL PEPTIDASE IV | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015691-A1 | SUBSTITUTED 8-AMINOALKYLTHIO-XANTHINES, AND THE USE THEREOF AS INHIBITORS OF THE DIPEPTIDYL PEPTIDASE IV | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | GPR119, INSR, GCKR | RXFP1 2955/4885MEN1 4115/4885KMT2A 2792/4885 |
| US-20070265284-A1 | SUBSTITUTED 8-AMINOALKYLTHIOXANTHINES, AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | DPP4, DPP8, DPP7 | RXFP1 3425/4885MEN1 3866/4885KMT2A 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.